Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Vermillion Receives Notice of Allowance from USPTO

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Company receives notice of allowance for patent on methods for diagnosing ovarian cancer.

Vermillion, Inc. has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Methods for Diagnosing Ovarian Cancer."

This patent further expands the list of biomarkers Vermillion has employed in the diagnosis or status determination of ovarian cancer.

In this case, the granted claims cover the use of Protein C Inhibitor (PCI) in ovarian cancer tests using blood and several other sample types.

"Vermillion continues to expand its already extensive portfolio of biomarker-related patents in ovarian cancer and other important disease states," said Donald Munroe, Ph.D., chief science officer and VP of research & development at Vermillion.

Munroe continued, "The latest patent allowance further strengthens the ovarian cancer franchise behind our lead product, OVA1®, and offers creative new options to detect and manage this silent killer."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vermillion Awarded $7.5M Grant
The grant awarded is to aid the development of a multi-site pelvic mass registry.
Friday, May 22, 2015
Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer
Patent makes claims in the uses of urinary sMAP in the diagnosis of ovarian cancer.
Tuesday, July 24, 2012
Vermillion Resolves Non-Contingent Claims with Bio-Rad
Vermillion to be returned more than $1 million from escrow.
Tuesday, May 01, 2012
Vermillion Receives Notice of Allowance for Patent on Platelet Biomarkers of Angiogenesis
Patented biomarkers used to measure ongoing angiogenic activity.
Tuesday, March 06, 2012
Vermillion Completes the Acquisition of Correlogic Systems' Ovarian Cancer Diagnostics Business for $435,000
The assets include more than 1,000 prospectively collected diagnostic samples from ovarian tumor studies, three biomarker-related pending U.S. patents, proprietary software and other intellectual property.
Thursday, December 22, 2011
Vermillion Announces Positive Top-Line Data from Intended Use Study for PAD
Study to develop and validate a biomarker panel applicable to the intended use population.
Tuesday, October 04, 2011
Vermillion Announces Issuance of Patent for Lung Cancer
The United States Patent and Trademark Office (USPTO) has issued patent number 8,014,952 entitled " Serum Biomarkers in Lung Cancer " to the Company.
Thursday, September 08, 2011
Vermillion Announces Notice of Allowance for Peripheral Artery Disease Patent
The patent covers biomarker panels for the diagnosis of Peripheral Artery Disease.
Monday, May 23, 2011
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos